drugset / Trial / NCT00375739

Study to Determine the Safety of PEP005 0.025% and 0.05% Topical Gel in Patients With Actinic Keratoses

NCT00375739

Phase 2 Completed 200 enrolled Peplin
RandomizedSingle-groupDouble-blindTreatment

Summary

The purpose of this study is to determine whether topical application of PEP005 is safe for the treatment of actinic keratoses.

Timeline

Start
2006-09
Primary completion
2007-06
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject ingenol mebutate Small molecule 0.025 % Topical
Subject ingenol mebutate Small molecule 0.05 % Topical

Indications